Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 2/20 | 0.34 |
| ▸ | DRD3 | P35462 | 2/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.33 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.33 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.33 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 2/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2852530 | 0.96 | HRH3 (0.43) | HRH3KCNH2USP30DRD2DRD3 | |
| SCHEMBL10779619 | 0.90 | GRIA1 (0.39) | HRH3KCNH2USP30DRD2DRD3 | |
| SCHEMBL9511984 | 0.90 | GRIA1 (0.39) | HRH3KCNH2USP30DRD2DRD3 | |
| SCHEMBL9349666 | 0.90 | GRIA1 (0.39) | HRH3KCNH2USP30DRD2DRD3 | |
| SCHEMBL9349673 | 0.90 | GRIA1 (0.39) | HRH3KCNH2USP30DRD2DRD3 | |
| SCHEMBL2850220 | 0.89 | GRIA1 (0.38) | HRH3KCNH2USP30DRD2DRD3 | |
| SCHEMBL4637129 | 0.89 | GRIA1 (0.38) | HRH3KCNH2USP30DRD2DRD3 | |
| SCHEMBL2352622 | 0.88 | GRIA1 (0.41) | HRH3KCNH2USP30DRD2DRD3 | |
| SCHEMBL7751867 | 0.88 | GRIA1 (0.41) | HRH3KCNH2USP30DRD2DRD3 | |
| SCHEMBL10338578 | 0.86 | KCNH2 (0.39) | HRH3KCNH2USP30DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100264368-A1 | LIQUID CRYSTAL MOLECULES COMPRISING HYDROAZULENE STRUCTURES | TETRAGON-CHEMIE AG (LI) | 2010-10-21 | — | — | US | disclosed |
| EP-1896552-B1 | LIQUID CRYSTAL MOLECULES COMPRISING HYDROAZULENE STRUCTURES | TETRAGON CHEMIE AG (LI) | 2010-05-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100264368-A1 | LIQUID CRYSTAL MOLECULES COMPRISING HYDROAZULENE STRUCTURES | FLI1, F12, GTF2I | HRH3 184/4885KCNH2 296/4885USP30 4264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.